PHASE II MULTICENTRIC AND PROSPECTIVE TRIAL WITH GEMCITABINE AND RAPAMYCIN IN SECOND LINE OF METASTATIC OSTEOSARCOMA - OSTEOSARCOMA METASTASICO PREVIOUSLY TREATED

JAVIER MARTÍN BROTO0 sitesApril 17, 2012

DrugsGEMCITABINE RAPAMUNE

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Not specified
Sponsor: JAVIER MARTÍN BROTO
Status: Active, not recruiting
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

April 17, 2012

End Date

TBD

Last Updated

13 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

JAVIER MARTÍN BROTO

Eligibility Criteria

Inclusion Criteria

•1\. Patient must willingly sign the informed consent before any trial tests that may not be part of the usual patient care, knowing the patient that he/she can leave the trial when desired, without this affecting the future attention.
•2\. Age equal or superior to 16 years.
•3\. Histological diagnosis of high\-grade osteosarcoma, metastatic or not operable in progression.
•4\. Previous treatment with drugs used in first line: Methotrexate, adriamycin, platin. It is not required having received ifosfamide for inclusion. They may have received mifamurtide in first line. Might have received bifosfonates though they will have to be interrupted 1 month before inclusion.
•5\. Measurable disease, according to RECIST criteria.
•6\. Functional state 0\-2 (ECOG).
•7\. Baseline medullary function (hemoglobin \> 10 g/dL, leukocytes ? 3\.000/mm3, RAN? 1,5 x 109 /l, granulocytes ? 1\.500/mm3, platelets ? 100\.000/mm3\). Acceptable patients with alteration of transaminases ? 2\.5 times normal limits, bilirubin total ? LSN, CPK? 2\.5 times normal limits, alkalyne phosphatase ? 2\.5 times more the normal limits or creatinine levels ? 1,6 mg/dL.
•8\. Patients in fertile age (both male and female) must use an effective contraceptive method before study entry and during the study. Furthermore, women must keep contraceptive measures until 3 months after finishing treatment while men must keep these measures up to 5 months after treatment. Pregnancy must be ruled out by urine test (negative pregnancy test) for inclusion in trial.
•9\. Normal cardiac functionality, considering the normal ranges of the institution.
•Are the trial subjects under 18? yes

Exclusion Criteria

•1\. Patients having been irradiated in the target lesions.
•2\. Functional state \> 2 (ECOG).
•3\. Bilirubin levels superior to normal level. Creatinine superior to 1\.6 mg/dL.
•4\. History of other tumor disease except basal\-cell carcinoma or carcinoma in situ of cervix adequately treated.
•5\. Serious cardiovascular diseases (Dyspnea \>\= 2 NYHA).
•6\. Systemic pathologies limiting survival to less than 2 years, limiting the availability of the patient, or that may interfere significantly with the treatment toxicity.
•7\. Infectious diseases: bacterial, viral or mycotic not controlled.
•8\. Pregnant patients or nurturing.
•9\. Psychological, familiar, sociological or geographical situations not allowing the fulfilment of the protocol or informed consent.
•10\. Patients currenly included in another clinical trial or receiving any agent under investigation.